Section snippets

Authors Contributions

AM drafted the letter. All authors (AM, MRP and ET) contributed equally to the study concept, reviewed and approved the final version of letter.

Financial Support

NilGEMA-Na: a crucial step in solving to the MELD-Creatinine dilemmaWe read with great interest the study by Dr Rosenstengle and colleagues examining MELD subtypes and the effect on intention-to-treat survival using the Scientific Registry of Transplant Recipients¹. In their comprehensive analysis, the authors clearly demonstrate that the creatinine subtype of MELD (MELD-Cr) conferred inferior survival at one-year compared to bilirubin or INR subtypes. Furthermore, females had poorer survival

Declaration of Competing Interest

No relevant conflicts of interest

中文翻译：

---

GEMA-Na：解决 MELD-肌酐困境的关键一步

 部分片段

 作者贡献

AM 起草了这封信。所有作者（AM、MRP 和 ET）对研究概念做出了同等贡献，审查并批准了信件的最终版本。

 财务支持

NilGEMA-Na：解决 MELD-肌酐困境的关键一步我们饶有兴趣地阅读了 Rosenstengle 博士及其同事的研究，该研究使用移植受者科学登记处¹ 研究了 MELD 亚型及其对意向治疗生存率的影响。在他们的综合分析中，作者清楚地表明，与胆红素或 INR 亚型相比，MELD 的肌酐亚型 （MELD-Cr） 的一年生存率较低。此外，雌性的存活率较差

利益争夺声明

无相关利益冲突